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Abstract
Background The use of psychotropic medications is not uncommon among patients with newly diagnosed cancer. However,
the impact of psychotropic polypharmacy on healthcare utilization during the initial phase of cancer care is largely unknown.
Methods We used a claims database to identify adults with incident breast, prostate, lung, and colorectal cancers diagnosed
during 2011–12. Psychotropic polypharmacy was defined as concurrent use of two or more psychotropic medication classes
for at least 90 days. A multivariable logistic regression was performed to identify significant predictors of psychotropic
polypharmacy. Multivariable Poisson and negative binomial regressions were used to assess the associations between psychotropic polypharmacy and healthcare utilization.
Results Among 5604 patients included in the study, 52.6% had breast cancer, 30.6% had prostate cancer, 11.4% had colorectal cancer, and 5.5% had lung cancer. During the year following incident cancer diagnosis, psychotropic polypharmacy was
reported in 7.4% of patients, with the highest prevalence among patients with lung cancer (14.4%). Compared with patients
without psychotropic polypharmacy during the initial phase of care, patients with newly diagnosed cancer with psychotropic
polypharmacy had a 30% higher rate of physician office visits, an 18% higher rate of hospitalization, and a 30% higher rate
of outpatient visits. The rate of emergency room visits was similar between the two groups.
Conclusion Psychotropic polypharmacy during the initial phase of cancer care was associated with significantly increased
healthcare resource utilization, and the proportion of patients receiving psychotropic polypharmacy differed by type of cancer.
Impact Findings emphasize the importance of evidence-based psychotropic prescribing and close surveillance of events
causing increased healthcare utilization among patients with cancer receiving psychotropic polypharmacy.

Key Points
Prevalence of psychotropic polypharmacy varied by
type of cancer and approximately 7.4% of patients with
cancer received psychotropic polypharmacy during the
first year following cancer diagnosis.
An abstract from a part of this study was presented as a poster
at the 2018 Internal Conference on Pharmacoepidemiology and
Therapeutic Risk Management, Prague, Czech Republic.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40801-019-0153-5) contains
supplementary material, which is available to authorized users.
* Ami M. Vyas
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Psychotropic polypharmacy was significantly associated
with higher rates of physician office visits, outpatient
visits, and inpatient visits.

1 Introduction
More than 1.5 million new cases of cancer are diagnosed
each year in USA [1] and mental health and adjustment
disorders are common among these patients [2, 3]. It is
Vol.:(0123456789)
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estimated that about 50% of patients diagnosed with cancer experience clinically significant psychosocial distress
and mental health disorders that may have a negative
impact on their quality of life [2, 4–6]. The Institute of
Medicine considers psychosocial care an essential part of
good-quality cancer care and recent treatment guidelines
have suggested the integration of psychosocial support and
mental health services into the routine care of patients
with cancer [7, 8]. Cancer by itself and its treatment
may precipitate several cancer-related symptoms such as
fatigue, pain, anorexia, sleep disturbances, and cognitive
dysfunction [9]. Psychotropic medications are widely used
to treat these cancer-related symptoms [10]. As a result,
psychotropic medications have become an important tool
in a multidisciplinary approach to mental health issues
related to cancer care [11]. These medications are often
prescribed for both psychiatric and non-psychiatric cancer
symptoms [12–18] by psychiatrists, oncologists, and primary care physicians, especially around the time of diagnosis and initial phase of cancer care (i.e., the first year
following cancer diagnosis) [19–21].
In routine medical practice, psychotropic polypharmacy
(PP), the concomitant use of two or more classes of psychotropic medications in one patient, is not uncommon
[22]. Although each drug may have an appropriate indication, this practice has received much attention in the
last decade because of increased pill burden, increased
healthcare cost, and safety concerns related to drug–drug
interactions not only between psychotropic medications,
but also between psychotropic medications and anticancer
medications [23–27]. Accordingly, the annual direct cost
of cancer care in USA is expected to rise from US$104
billion in 2006 to about US$173 billion by 2020 with a
corresponding increase in healthcare resource utilization
[28, 29]. A few studies have described the use of psychotropic medications in patients with cancer [17–21, 30–32]
but none have examined the impact of PP on healthcare
resource utilization during the initial phase of cancer
care when initial courses of cancer treatment including
adjuvant therapy are usually expected to be completed.
This period of active cancer treatment is characterized by
significant psychosocial distress, psychotropic medication use, and frequent clinical encounters. Prior studies
have shown healthcare resource utilization and cancerrelated costs to vary by several factors including cancer
type, stage at diagnosis, sex, and area of residence [33,
34] with the greatest expenditure occurring among those
with metastatic cancer, especially during the last year of
life [34–36]. The purpose of the study was to examine the
prevalence of PP, and the relationship between PP and
healthcare resource utilization during the year following
the initial diagnosis of breast, prostate, lung, and colorectal cancers.
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2 Methods
2.1 Study Design and Data Source
This cross-sectional observational study was conducted
using an administrative claims database, Optum Clinformatics ® Data Mart (OptumInsight, Eden Prairie, MN,
USA), covering about 22 million enrollees across USA
from 2010 to 2013. Beneficiaries included in the database
had both medical and prescription drug coverage. The
database included demographic and enrollment information as well as medical and pharmacy claims. The inpatient
file captured information on counts of hospitalization and
lengths of hospital stays. The database is licensed to the
University of Rhode Island, College of Pharmacy and the
study protocol was approved by the Institutional Review
Board of the University of Rhode Island (Kingston, RI,
USA).

2.2 Study Population
The study was limited to breast, prostate, lung, and colorectal cancers, which represent the most common cancers
among adults in USA and accounted for 46.3% (US$48
billion) of the national economic burden of cancer care in
2006 [29, 37]. We used the following International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify cancer cases diagnosed
between 1 January, 2011 and 31 December, 2012: 174.xx,
175.xx, 233.0x for breast, 185.xx, 233.4x for prostate,
153.xx, 154.xx, 230.3x, 230.4x for colorectal, and 162.xx,
231.2x for lung cancer [38]. Each patient was required to
have at least two separate medical claims with the same
cancer diagnosis having service dates at least 30 days
apart. The index date was defined as the date of service
for the initial cancer diagnosis. To allow for adequate
ascertainment of baseline characteristics and subsequent
assessment of study outcomes, the analysis was restricted
to patients with continuous enrollment having both medical and pharmacy benefits for 12 months before and after
the index date. The baseline period was defined as the
12 months preceding the cancer diagnosis and healthcare
resource utilization was assessed during the initial phase
of cancer care. We also excluded patients aged younger
than 18 years, female patients with any claims for prostate
cancer, male patients with claims for breast cancer, and
patients with more than one type of cancer or claim for
metastatic cancer (ICD-9-CM: 196.xx to 198.x) at baseline
or during the initial phase of cancer care. We excluded
patients with any known metastatic disease because it is
not possible to differentiate de novo metastatic cancer
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from a metastasis occurring following primary incident
cancer diagnosis using claims data without a chart review.
The flow chart for the study cohort selection process is
shown in Table 1.

2.3 Study Measures
2.3.1 Psychotropic Polypharmacy
Psychotropic prescription information was obtained from
outpatient pharmacy claims and categorized using the American Hospital Formulary Service Pharmacologic Therapeutic Classification System therapeutic class codes. Psychotropic medication were categorized by drug class according
to their standard use as antidepressants, antipsychotics,
anticonvulsants, anxiolytics-sedatives-hypnotics (including
barbiturates), and central nervous system stimulants/psychostimulants. These classes of psychotropic medications were
selected based on published reviews about the use of psychotropic medications among patients with cancer [39, 40].
Psychotropic medication use was defined as the receipt of at
least one prescription in the psychotropic medication classes
during the study period. Psychotropic polypharmacy was
defined as the concurrent use of two or more psychotropic
medication classes for at least 90 days [25, 41, 42].
2.3.2 Healthcare Resource Utilization
Healthcare Common Procedure Coding System procedure
codes, place of service, and revenue codes were used to identify specific types of healthcare resource utilization including office visits, outpatient visits, and emergency room (ER)
visits during the initial phase of care. We used the inpatient
data file to identify inpatient admissions and length of inpatient stay during the initial phase of care. Multiple claims
with the same procedure code, place of service, and claim
date were considered duplicates and only one claim was considered for assessing healthcare utilization. Each claim was
treated as a distinct medical encounter, visit, or event. Office
visits included claims for services performed in a physician’s
office while outpatient visits included encounters outside a
doctor’s office for which a patient is able to return home after
care without an overnight stay including visits to hospital
Table 1  Study cohort selection

outpatient departments, oncology clinics, ambulatory care
surgical centers, outpatient rehabilitation facilities, rural
health clinics, and community mental health centers. Office
visits were identified with procedure codes 99201–99205
and 99211–99215; outpatient visits with procedure codes
99241–9245, 99341–99350, 99381–99387, 99391–99397,
99401–99404, 99411, 99412, 99420, 99429, 99455, and
99456; and ER visits with procedure codes 99281–99288.
2.3.3 Covariates
Demographic characteristics obtained from the membership file included age at initial cancer diagnosis, sex, type
of health plan (point of service, exclusive provider organization, health maintenance organization, and others), and
US geographic census region (Northeast, South, Midwest,
and West). Clinical characteristics consisted of the type of
cancer (breast, prostate, lung, colorectal), Charlson comorbidity indices, psychiatric comorbidities, and chemotherapy
and radiation therapy; the latter were captured with ICD9-CM codes V58.11 and V58.0, respectively. Charlson
comorbidity indices were calculated for each patient based
on the presence of claims for certain diagnosis during the
year prior to cancer diagnosis [43]. In addition to dementia
being included in the Charlson comorbidity measure, we
also controlled additional baseline psychiatric conditions
such as depression, anxiety, dysthymia, post-traumatic stress
disorder, bipolar disorder, personality disorder, schizophrenia, and other psychotic disorders [32, 44, 45]. These were
obtained from the medical file using their respective ICD9-CM codes.

2.4 Statistical Analysis
Descriptive statistics were computed for baseline demographic and clinical characteristics and differences between
patients with and without PP during the initial phase of care
were compared using Chi-square goodness-of-fit tests (for
categorical variables) and t tests (for continuous variables).
The prevalence of PP overall and by type of cancer were
also estimated and compared using t tests. The mean number
of prescriptions for psychotropic medications prescribed to
patients and the prevalence of PP during the baseline period

N

Criteria met

26,064
15,292
15,279
14,733
14,176
5604

Claims for one type of cancer between 1/1/2011 and 31/12/2012
Continuous enrolled for 1 year before and after cancer diagnosis
After excluding male with female individuals with cancers and vice versa
After excluding patients with metastatic cancer during initial phase of care
After excluding patients aged younger than 18 years
Patients with breast, prostate, lung, and colorectal cancers only
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and initial phase of care overall and by type of cancer were
estimated using t tests. To identify potential predictors of
PP among patients with cancer, first, a multivariable logistic
regression model was conducted.
The frequency and rates of office visits, outpatient visits, ER visits, inpatient admissions, and length of inpatient
stay during the initial phase of cancer care were determined.
The unadjusted cumulative incidence rate for each type of
healthcare resource utilization was computed as the sum of
all events or the total number of patients who experienced
the incident event of interest per cohort divided by the total
person-time at risk for the entire cohort [46]. Second, multivariable regressions were performed to evaluate if PP vs.
no PP was associated with each component of healthcare
resource utilization. Adjusted incidence rate ratios (aIRRs)
were estimated using either a Poisson (number of admissions) or a negative binomial (number of outpatient visits,
office visits, ER visits, and hospital length of stay) regression based on a model fit for our data, after controlling for all
the covariates (Appendix 1 of the Electronic Supplementary
Material [ESM]). A goodness-of-fit Chi-square test was used
to assess the fit of each model assuming that the deviance
follows a Chi-square distribution with degrees of freedom
equal to the model residual [47] (eTable 3 of the ESM).
All statistical analyses were two sided and conducted at
the 0.05 significance level. Statistical analyses were performed using the Statistical Analysis Systems software
(SAS® Version 9.4, SAS Institute Inc., Cary, NC, USA).

3 Results
3.1 Study Population and Baseline Characteristics
A total of 5604 patients with newly-diagnosed cancer were
included in the study, of which 52.6% had breast cancer,
30.6% had prostate cancer, 11.4% had colorectal cancer, and
5.5% had lung cancer. Four hundred and sixteen patients
(7.4%) received PP during the initial phase of cancer care
(Table 2). Overall, more than 77% of patients were between
the ages of 45 and 64 years, 61% were female, 74.6% had
a point of service health plan, and 68% received medical
care in the Southern US census region. A majority of these
patients had a Charlson comorbidity score of 0 (66.5%)
or did not have any diagnoses for psychiatric conditions
(93.8%) at baseline. The distributions of clinical and demographic characteristics among patients who received PP during the year following cancer diagnosis were significantly
different from those without PP, except for type of health
plan. At baseline, a majority of patients prescribed PP were
more likely to be female (81.3%) aged 55–64 years (56.5%)
with breast cancer (65.1%) as compared to those without
PP. Furthermore, patients who received PP during the initial
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phase of care were more likely to have a Charlson comorbidity index of at least 1 and mental illness before cancer
diagnosis compared with patients who did not receive PP. A
total of 39,001 psychotropic medication prescriptions were
filled during the 2-year period around initial cancer diagnoses, of which 20,970 (53.8%) were prescribed during the
initial phase of care, 18,336 (47%) were antidepressants,
and 13,252 (34%) were anxiolytics (eTable 1 of the ESM).

3.2 Prevalence and Predictors of Psychotropic
Polypharmacy
The proportion of patients who received PP during the
1 year prior to cancer diagnosis increased among all types
of cancers during the initial phase of cancer care (Table 3).
On average, the proportion of patients on PP increased significantly from 6.2% before to 7.4% after cancer diagnosis.
More than 90% of patients who received PP during the initial
phase of care had an antidepressant as a component of their
PP combination (eTable 2 of the ESM). Use of PP during
the initial phase of care differed by cancer type, with patients
with lung cancer (14.4%) more likely to have PP compared
with patients with breast (9.2%), prostate (2.9%), or colorectal (8.0%) cancers. There was a corresponding increase in
the average number of psychotropic drug prescriptions during the 12 months preceding the index date compared with
the 12 months following the initial cancer diagnosis for all
types of cancers, except for a relatively small but statistically
non-significant decrease among patients with lung cancer
(Table 4). For instance, the mean number of psychotropic
drug prescriptions among patients with colorectal cancer
increased from 7.95 (standard deviation = 8.97) at baseline
to 8.91 (standard deviation = 8.90) during the initial phase
of care.
Sex, age group at cancer diagnosis, presence of psychiatric conditions, and physical comorbidity at baseline were
significant predictors of the use of PP during the initial
phase of cancer care (Table 5). After controlling for other
variables in the model, patients aged 55–64 years were more
likely to receive PP compared with those aged 18–44 years
(adjusted odds ratio [aOR] = 1.69; 95% confidence interval [CI] 1.07–2.65); female patients were two times more
likely to receive PP than male patients (aOR = 2.15; 95% CI
1.32–3.49); and patients with cancer residing in the South
were 1.5 times more likely to use PP than those residing in
the Northeast (aOR = 1.51; 95% CI 1.09–2.08). In addition,
patients with cancer with one or more psychiatric diagnostic
conditions (aOR = 8.39; 95% CI 6.32–11.19 for one condition; aOR = 11.19; 95% CI 6.42–19.52 for two or more
conditions) were more likely to receive PP compared with
those without any psychiatric condition at baseline. Finally,
patients with cancer with at least one comorbidity score
(aOR = 1.70; 95% CI 1.32–2.18 for one score; aOR = 2.21;
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Table 2  Baseline characteristics
of patients diagnosed with
breast, prostate, lung, and
colorectal cancers in USA
(n = 5604)

Characteristics
Age group at index (years)
18–44
45–54
54–64
65+
Sex
Female
Male
Type of health plan
EPO
HMO
Othersa
POS
Geographic region
Midwest
Northeast
South
West
Type of cancer
Breast
Colorectal
Lung
Prostate
No. of psychiatric conditions
None
1
2+
Charlson Comorbidity Index
0
1
2+

Overall
n = 5604

No PP
n = 5188 (92.6%)

PP
n = 416 (7.4%)

P value

408 (7.28)
1505 (26.86)
2822 (50.36)
869 (15.51)

382 (7.36)
1396 (26.91)
2587 (49.87)
823 (15.86)

26 (6.25)
109 (26.20)
235 (56.49)
46 (11.06)

0.0202

3418 (60.99)
2186 (39.01)

3080 (59.37)
2108 (40.63)

338 (81.25)
78 (18.75)

<0.0001

727 (12.97)
295 (5.26)
401 (7.16)
4181 (74.61)

679 (13.09)
277 (5.34)
359 (6.92)
3873 (74.65)

48 (11.54)
18 (4.33)
42 (10.10)
308 (74.04)

0.0748

1582 (28.23)
1042 (18.60)
2265 (40.40)
714 (12.74)

1466 (28.26)
978 (18.85)
2073 (39.97)
670 (12.92)

116 (27.88)
64 (15.38)
192 (46.15)
44 (10.58)

0.0500

2946 (52.57)
636 (11.35)
306 (5.46)
1716 (30.62)

2675 (51.56)
585 (11.28)
262 (5.05)
1666 (32.11)

271 (65.14)
51 (12.26)
44 (10.58)
50 (12.02)

< 0.0001

5256 (93.79)
288 (5.14)
60 (1.07)

4967 (65.74)
189 (3.64)
32 (0.62)

289 (69.47)
99 (23.80)
28 (6.73)

< 0.0001

3729 (66.54)
1252 (22.34)
623 (11.12)

3513 (67.71)
1129 (21.76)
546 (10.52)

216 (51.92)
123 (29.57)
77 (18.57)

< 0.0001

EPO exclusive provider organization, HMO health maintenance organization, POS point of service, PP
psychotropic polypharmacy

a

Others include indemnity and preferred provider organizations

Table 3  Distribution of psychotropic polypharmacy among adults
with common cancer types in USA

95% CI 1.61–3.04 for two or more scores) were more likely
to have PP compared with those without any physical comorbidity at baseline.

Cancer types Total population, n
(%)

Baseline, n (%) Initial phase
of care, n (%)

3.3 Rates of Healthcare Resource Utilization

Breast
Colorectal
Lung
Prostate
Overall

229 (7.77)
42 (6.60)
30 (9.80)
44 (2.56)
345 (6.16)

Nearly 45% of all patients had at least one outpatient and
office visit, 18.5% required at least one hospital admission,
and 15.7% had at least one ER visit during the initial phase
of cancer care. Table 6 presents a summary of the unadjusted
and adjusted rates of healthcare resource utilization among
patients with cancer with and without PP during the initial
phase of cancer care. After adjusting for age at cancer diagnosis, sex, type of health plan, geographic region, cancer

2946 (52.57)
636 (11.35)
306 (5.46)
1716 (30.62)
5604

271 (9.20)
51 (8.02)
44 (14.38)
50 (2.91)
416 (7.42)

The proportion of patients with psychotropic polpharmacy at baseline
and during the initial phase of care differed significantly for all cancer
types (Chi square test: p < 0.0001)
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prescriptions of psychotropic
medications among adultsa with
common cancer types in USA
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Cancer types

Breast
Colorectal
Lung
Prostate
Overall

At baseline

During the initial phase of care

N (%)

Mean (95% CI)

N (%)

Mean (95% CI)

1388 (62.21)
231 (10.35)
159 (7.13)
453 (20.30)
2231 (100)

8.45 (7.98–8.92)
7.95 (6.79–9.11)
10.14 (8.49–11.78)
6.30 (5.63–6.96)
8.08 (7.72–8.45)

1518 (63.28)
262 (10.92)
181 (7.54)
438 (18.26)
2399 (100)

9.00 (8.53–9.47)
8.91 (7.83–10.00)
10.03 (8.50–11.55)
7.22 (6.53–7.92)
8.74 (8.38–9.11)

CI confidence interval
The mean number of psychotropic medications used at baseline and during the initial phase of cancer care
did not differ significantly both overall and for each type of cancer (t test: p > 0.05)
a

Among those with at least one psychotropic medication prescription during baseline or during the initial
phase of care

type, number of psychiatric conditions and Charlson comorbidity index at baseline, and use of radiation and chemotherapy during the initial phase of cancer care, patients who
received PP had about a 30% higher rate of both outpatient
and physician office visits (aIRR = 1.28; 95% CI 1.21–1.36
and aIRR = 1.30; 95% CI 1.23–1.38, respectively), 18%
higher rates of hospital admissions (aIRR = 1.18; 95% CI
1.07–1.31), and a 30% increase in the length of hospital
inpatient stays (aIRR = 1.30; 95% CI 1.11–1.52), than those
without PP. The rates of ER visits were 4% higher among
patients who received PP than those who did not receive PP
but this difference was not statistically significant. A more
detailed result of the adjusted models estimated using the
Poisson and negative binomial regressions is provided in
eTable 3 of the ESM.

4 Discussion
Several cancer- or cancer treatment-related symptoms are
managed with psychotropic medications [9, 10, 19–21, 48].
In certain clinical situations, the use of more than one psychotropic medication is appropriate and supported by empirical evidence. For example, the addition of antipsychotics to
either antidepressants for the treatment of major depression
with psychotic features [49] or to mood stabilizers for the
management of acute mania [50] is considered the standard
of care. Similarly, the short-term use of benzodiazepines
with antidepressants to treat major depression may be clinically justified [51]. Furthermore, patients with treatmentresistant disease may require dual therapy, and for many
patients, depression, anxiety, pain, and psychosis may coexist, warranting the use of multiple psychoactive medications.
We examined the prevalence of PP, predictors of the
use of PP during the initial phase of cancer care, and the
association between the use of PP and healthcare resource
utilization. We found that the proportion of patients who
received PP increased slightly from the baseline period to

the initial phase of cancer care among all patients and for
all cancer types included in our study. Prevalence of psychotropic medication use and PP at baseline were relatively
low (6.2%), likely because most patients in our cohort did
not have any psychiatric conditions during the year leading
up to their first cancer diagnosis. A previous study found
that the risk of mental health disorders is temporally related
to the diagnostic work-up for suspected cancer with a corresponding increased use of psychotropic medications from
about a month before a cancer diagnosis that peaks at about
3 months after [52]. This may explain the modest overall
increase in the prevalence of PP use from 6.2% at baseline
to 7.4% after cancer diagnosis in our study sample.
In this study, we found that in addition to the number of
psychiatric conditions at baseline, sex, age at cancer diagnosis, and physical comorbidity at baseline were also significant predictors of the use of PP during the initial phase
of cancer diagnosis. Type of cancer was not a significant
predictor of PP use during the initial phase of cancer care.
This finding is partially similar to that reported in a previous
study that showed no significant association between type
of cancer and the use of antidepressants [53]. Other studies
have found a similarly higher prevalence of psychotropic
medication use and PP among women and patients with
comorbid conditions [21, 30, 54].
A higher prevalence of PP was observed among patients
with lung, colorectal, and breast cancers compared with
those with prostate cancer. These findings are consistent
with those reported in an analysis of self-reported medication use among survivors of patients with breast, lung, and
colorectal cancers [30]. A retrospective cohort study of community-based Medicare beneficiaries also found that patients
with prostate cancer were least likely to receive any psychotropic medications compared with patients with breast, lung,
and colorectal cancers [55]. One potential reason for a lower
prevalence of PP among patients with prostate cancer is that
a diagnosis of prostate cancer may be associated with less
psychosocial distress requiring pharmacotherapy because a
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Table 5  Factors associated
with use of psychotropic
polypharmacy among adults
with common cancer types
during the year following cancer
diagnosis in USA

Variables
Age group at index (years)
18–44
45–54
54–64
65+
Sex
Male
Female
Type of health plan
HMO
EPO
Othersa
POS
Geographic region
Northeast
Midwest
South
West
Type of cancer
Breast
Colorectal
Lung
Prostate
Chemotherapy
No
Yes
Radiotherapy
No
Yes
No. of psychiatric conditions
None
1
2+
Charlson Comorbidity Index
0
1
2+

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

Ref.
1.15 (0.74–1.79)
1.34 (0.88–2.03)
0.82 (0.50–1.35)

Ref
1.25 (0.78–2.00)
1.69 (1.07–2.65)
1.13 (0.65–1.97)

Ref.
2.97 (2.30–3.82)

Ref
2.15 (1.32–3.49)

Ref.
1.09 (0.62–1.90)
1.80 (1.01–3.20)
1.22 (0.75–2.00)

Ref.
1.03 (0.57–1.87)
1.82 (0.98–3.39)
1.27 (0.76–2.14)

Ref.
1.21 (0.88–1.66)
1.42 (1.06–1.90)
1.00 (0.678–1.49)

Ref.
1.26 (0.89–1.77)
1.51 (1.09–2.08)
1.13 (0.74–1.73)

Ref.
0.86 (0.630–1.18)
1.66 (1.176–2.34)
0.30 (0.218–0.40)

Ref.
1.29 (0.89–1.88)
1.46 (0.96–2.22)
0.62 (0.35–1.12)

Ref.
1.46 (1.07–1.98)

Ref.
1.15 (0.81–1.64)

Ref.
1.00 (0.673–1.47)

Ref.
0.86 (0.55–1.33)

Ref.
9.00 (6.87–11.80)
15.04 (8.93–25.32)

Ref.
8.39 (6.32–11.13)
11.19 (6.42–19.52)

Ref.
1.77 (1.41–2.23)
2.29 (1.74–3.02)

Ref.
1.70 (1.32–2.18)
2.21 (1.61–3.04)

Bold values indicate p < 0.05
CI confidence interval, EPO exclusive provider organization, HMO health maintenance organization, OR
odds ratio, POS point of service

a

Others include indemnity and preferred provider organizations

significant portion of patients with prostate cancer die with
the disease rather than from the disease.
We found that the use of PP during the first year after
a cancer diagnosis was associated with increased rates of
outpatient visits, office visits, inpatient admissions, and
length of hospital stay after adjusting for certain potential confounding factors. Patients with newly diagnosed
cancer often require chemotherapy and concurrent use of

multiple psychotropic medications places them at a significantly higher risk of adverse drug–drug interactions
that may require additional healthcare services for their
effective management [24, 27, 56]. Patients who received
PP in our study were more likely to have many chronic
physical and psychiatric conditions. This may explain why
they experienced more frequent clinical encounters and
received more psychotropic medications. To the best of
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Table 6  Unadjusted and adjusted rates of healthcare resource utilization during the initial phase of cancer care comparing patients with
psychotropic polypharmacy (PP) and without PP among adults with
common cancer types in USA
Adjusted IRR (95% CI)a

Healthcare resource
utilized

Unadjusted IRR

Number of outpatient
visits
Number of office visits
Number of ER visits
Number of admissions
Length of stay (days)

1.25 (1.21–1.28) 1.28 (1.21–1.36)
1.26 (1.23–1.29)
1.19 (1.09–1.29)
1.27 (1.16–1.40)
1.34 (1.25–1.43)

1.30 (1.23–1.38)
1.04 (0.88–1.23)
1.18 (1.07–1.31)
1.30 (1.11–1.52)

Bold values indicate p < 0.05
CI confidence interval, ER emergency room, IRR incidence rate ratio
a

Adjusted for age at index, sex, type of health plan, geographic
region, cancer type, psychiatric conditions, and Charlson Comorbidity Index at baseline, and use of radiation and chemotherapy during
the initial phase of cancer care

the authors’ knowledge, this is the first study to examine
the prevalence and predictors of PP during the first year of
cancer care among patients with newly diagnosed breast,
prostate, lung, and colorectal cancers in USA using a large
insured adult population.
Our study design has some limitations. First, multiclass
PP relies on a grouping of psychotropic medications into
classes that is based on certain clinical syndromes or mechanisms of action that may not fully capture their pharmacological properties. In recent years, some psychotropic
medications have received approvals for multiple indications. Because we did not assess the appropriateness of PP
or adverse effects, we do not know if increased healthcare
utilization is directly attributable to the consequences of PP
or mental healthcare. In addition, some information that may
impact on the use of psychotropic medications on healthcare resource utilization was not captured in our data source.
Specifically, data on variables such as race/ethnicity, socioeconomic status, clinical information about the cancer (e.g.,
severity, tumor stage, tumor size, and tumor grade), performance status, and patient preferences and beliefs about alternative treatments was not available in the extant database.
Second, a cross-sectional design limits our ability to make
causal inferences owing, in part, to lack of temporality. We
also conditioned our analysis on survival during the initial
phase of care and occurrence of metastatic disease measured
after baseline, which could induce selection bias. As a result,
the true rates of PP among patients with cancer are likely
higher than our estimates because psychotropic medication
use often starts during evaluations for suspected cancer and
peaks after cancer diagnosis, and may persist during terminal care [21]. Patients who had more advanced cancers
and died during the initial phase of care were excluded,
which may have resulted in healthier patients included in

our analysis, as compared to all patients with incident cancer
in the database. The list of procedure codes for office visits
may not be exhaustive. Last, the study focused only on a
commercially insured population, hence the findings may
not be generalizable to other populations.

5 Conclusion
Patients with PP during the initial phase of cancer care utilized more healthcare resources than those without PP. There
was a small but statistically significant increase in the use of
psychotropic medications and PP after initial cancer diagnosis, and the proportion of patients receiving PP differed
by the type of cancer. Given current treatment guideline recommendations, this increase may be the result of a greater
inclusion of a psychiatrist specialized in psycho-oncology
in multidisciplinary cancer care teams, and the availability
of newer psychotropic medications. Psychotropic medication use may be an indicator of better assessments of psychosocial distress associated with a new cancer diagnosis.
These findings emphasize the importance of evidence-based
psychotropic prescribing and close surveillance for potential
adverse psychotropic drug–drug interactions in patients with
cancer, and suggest that patients with cancer with mental
health illnesses, even when treated, require a higher degree
of healthcare services. Further research is needed to determine the proportion of increased healthcare resource utilization in this population attributable to the underlying mental
health co-morbidity, or psychotropic medication side effects,
interactions, or other potential adverse outcomes of therapy.
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